31. Three-year efficacy of zoledronic acid therapy for osteoporosis in postmenopausal women at Hai Phong International General Hospital
Main Article Content
Abstract
Zoledronic acid (ZOL) is a new generation bisphosphonate that is recommended for osteoporosis therapy because it effectively increases bone mineral density (BMD) and mitigates the risk of osteopenic progression. This study sought to quantify BMD gains at the lumbar spine (LS) and femoral neck (FN) after 12 and 24 months of ZOL infusion and to evaluate treatment safety. A three year retrospective analysis (2022 - 2024) was conducted on 183 postmenopausal women with osteoporosis (T score < -2.5) who received ZOL. At the FN, mean BMD increased by 4.1% after one year (p < 0.05) and by 5.5% after two years relative to baseline (p < 0.05). At the LS, mean BMD rose by 5.3% at one year (p < 0.05) and by 6.2% at two years compared with baseline (p < 0.05). The findings from Hai Phong International General Hospital demonstrate that an annual 5mg intravenous infusion of zoledronic acid produces significant, sustained improvements in BMD and exhibits a favorable safety profile in postmenopausal women with osteoporosis.
Article Details
Keywords
Osteoporosis, zoledronic acid, bone mineral density
References
2. Greenspan SL, et al. (1994). Rate of bone loss in postmenopausal women with normal bone mineral density. JAMA. 271(16):1953–1956. PMID: 8158839
3. Riggs BL, Khosla S, Melton LJ 3rd. (2002). Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 23(3): 279–302.DOI: 10.1210/er.23.3.279.
4. Clynes MA, Harvey NC, Curtis EM et al. Global prevalence of osteoporosis in postmenopausal women: a crosssectional review. 2023.
5. Hoang DK, Doan MC, Mai LD et al. Burden of osteoporosis in Vietnam: An analysis of population risk. PLoS One. 2021; 16(6): e0252592.
6. Nguyen HT, Nguyen BT, Thai THN et al. Prevalence, incidence of and risk factors for vertebral fracture in the community: the Vietnam Osteoporosis Study. Sci Rep. 2024; 14:32
7. Black DM, Delmas PD, Eastell R et al. Onceyearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356: 18091822.
8. D’Andrea E, Schneeweiss S, Franklin JM et al. Efficacy versus effectiveness: the HORIZONPivotal Fracture Trial and its emulation in claims data. Arthritis Rheumatol. 2025; 77(1): 1221.
9. WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series 843. Geneva: World Health Organization; 1994.
10. Kanis JA, et al. FRAX® and the assessment of fracture probability in men and women from the UK. Osteoporosis International. 2008; 19(4), 385–397. DOI: 10.1007/s00198-007-0543-5.